Retatrutide vs tirzepatide: is retatrutide just a stronger Mounjaro?

“Is retatrutide just stronger Mounjaro?” is the question that keeps coming back in weight-loss threads, usually from people who have already been on tirzepatide for a while. The short version: both come from Eli Lilly, both are once-weekly injections built on the same incretin idea, and retatrutide adds one more receptor to the recipe. That extra receptor changes the side-effect profile as well as the weight numbers, and the two drugs have never been compared in a finished head-to-head trial. This page puts them side by side from the trial papers, the Zepbound label and Lilly’s own releases, then looks at what the community conversation gets right.

Is retatrutide the same as tirzepatide?

No. Tirzepatide is a dual agonist that activates two gut-hormone receptors, GIP and GLP-1, and it is an approved drug sold as Zepbound and Mounjaro (Zepbound label, DailyMed). Retatrutide (research code LY3437943) is a separate peptide molecule that activates three receptors, GIP, GLP-1 and glucagon, and it is still investigational (Coskun et al., Cell Metabolism, 2022). They share a developer and a drug family, but retatrutide is not a higher dose or a new version of tirzepatide.

Retatrutide vs tirzepatide at a glance

The table compares the two on the points people ask about most. The weight figures come from separate trials with different lengths, populations and analysis methods, so they show the size of each drug’s effect, not a winner.

Retatrutide vs tirzepatide. Trial figures are from separate studies and are not a head-to-head result. Sources are linked in the sections on this page.

Attribute	Retatrutide	Tirzepatide (Zepbound, Mounjaro)
Receptors activated	GIP, GLP-1 and glucagon (triple agonist)	GIP and GLP-1 (dual agonist)
Status, October 2026	Investigational; not FDA-approved	Approved: Zepbound for weight and sleep apnea, Mounjaro for type 2 diabetes
Evidence level	Large randomized phase 3 trials; mostly company toplines, one phase 3 paper published	Approved drug with published phase 3 trials and an FDA label
How it was given in trials	Once weekly; 4, 9 or 12 mg after stepping up from 2 mg	Once weekly; 5, 10 or 15 mg after a step-up period
Average weight change, obesity without diabetes (all randomized, highest dose)	-25.0% at 80 weeks, TRIUMPH-1 (placebo -3.9%)	-20.9% at 72 weeks, SURMOUNT-1 (placebo -3.1%)
Nausea at the highest dose	42.4% vs 14.8% placebo (TRIUMPH-1)	28% vs 8% placebo (Zepbound label)
Dysesthesia (abnormal skin sensation)	5.1% to 12.5% vs 0.9% placebo (TRIUMPH-1)	0.2% to 0.4% vs 0.1% placebo (Zepbound label)
Stopped for side effects, highest dose	11.3% vs 4.9% placebo (TRIUMPH-1)	6.7% vs 3.4% placebo (Zepbound label)
How people can get it	Lilly trials and a limited expanded access program	Prescription

How does retatrutide work, and how is that different from tirzepatide?

Retatrutide works by switching on three receptors at once, where tirzepatide switches on two. The Zepbound label describes tirzepatide as a drug that “selectively binds to and activates both the GIP and GLP-1 receptors”, with GLP-1 acting as a regulator of appetite and calorie intake (Zepbound label, DailyMed). Retatrutide adds the glucagon receptor. In Lilly’s discovery paper, obese mice given retatrutide ate less through the GIP and GLP-1 activity, and the glucagon activity added an increase in energy expenditure on top (Coskun et al., 2022).

That energy-expenditure finding is the main theory for why a triple agonist could beat a dual one, but it comes from animal work. The human trials measured weight and health markers, not how much of the effect each receptor contributes. For the basics of how this drug family works, see how GLP-1 medications work for weight loss.

Is retatrutide a GLP-1?

Partly. Retatrutide does activate the GLP-1 receptor, so it belongs to the broad GLP-1 family, but it is not only a GLP-1 drug: it also activates the GIP and glucagon receptors (Jastreboff et al., NEJM, 2023). Tirzepatide is likewise more than a GLP-1, since it adds GIP. Calling retatrutide “GLP-3” online is a nickname for its three targets, not a scientific term.

Is retatrutide the same as Ozempic?

No. Ozempic is semaglutide, which targets one receptor, GLP-1. Tirzepatide adds GIP, and retatrutide adds glucagon on top of that, so the three drugs form a ladder of one, two and three receptor targets (The Guardian, August 31, 2026). How the first two compare directly, including the SURMOUNT-5 head-to-head trial, is covered in semaglutide vs tirzepatide.

Which produces more weight loss: retatrutide or tirzepatide?

Retatrutide has produced larger average weight loss in its own trials than tirzepatide did in its own, but no completed trial has compared them directly. In TRIUMPH-1, 2,339 adults with obesity, or overweight plus at least one weight-related condition, and no diabetes took retatrutide or placebo for 80 weeks. Counting everyone regardless of whether they kept taking the drug (the “treatment-regimen” estimand), the 12 mg group lost 25.0% of body weight on average against 3.9% on placebo; Lilly’s headline figure of 28.3% is the “efficacy” estimand, which estimates the effect had everyone stayed on treatment (Lilly, May 21, 2026).

In SURMOUNT-1, 2,539 adults with obesity or overweight and no diabetes took tirzepatide or placebo for 72 weeks. Using the same treatment-regimen approach, the 15 mg group lost 20.9% against 3.1% on placebo, and 57% of that group lost at least 20% of their weight (Jastreboff et al., NEJM, 2022).

Matched like for like, the gap is roughly 25% versus 21%, not the 28% versus 21% that circulates online, and the trials ran for different lengths. Earlier phase 2 work pointed the same way: 12 mg of retatrutide produced a 24.2% average loss at 48 weeks in 338 adults (Jastreboff et al., 2023). In people with type 2 diabetes the numbers drop for both drug families; in TRIUMPH-2, published in The Lancet, retatrutide 12 mg produced an average 18.8% loss at 80 weeks against 5.1% on placebo (Bellido et al., Lancet, 2026).

Has retatrutide been tested head to head against tirzepatide?

Yes, a direct comparison is under way, but it has not reported. TRIUMPH-5 is a phase 3, randomized, double-blind trial of retatrutide against tirzepatide in adults with obesity, with the percent change in body weight at 80 weeks as its main outcome. The registry lists it as active and not recruiting, with an estimated 800 participants and an estimated primary completion date of November 2026 (ClinicalTrials.gov, NCT06662383). Until it reports, every “retatrutide beats tirzepatide by X%” claim is a cross-trial comparison. PeptideAgent’s retatrutide vs tirzepatide comparison makes the same point, and sets tirzepatide’s approved labels against retatrutide’s investigational status.

How do the side effects compare?

Both drugs mainly cause stomach and gut side effects, but retatrutide’s rates ran higher at its top dose and it carries two signals tirzepatide shows far less: skin-sensation changes and a larger heart-rate rise. In TRIUMPH-1, nausea affected 28.6%, 38.4% and 42.4% of people on 4, 9 and 12 mg against 14.8% on placebo, vomiting reached 25.3% on 12 mg against 4.8% on placebo, and 11.3% on 12 mg stopped because of side effects against 4.9% on placebo (Lilly, May 21, 2026). On the Zepbound label, which pools two trials that together included people with and without type 2 diabetes, nausea affected 25% to 29% across doses against 8% on placebo, and 4.8% to 6.7% stopped for side effects against 3.4% (Zepbound label, DailyMed).

The differences worth knowing:

• Dysesthesia. Abnormal skin sensations occurred in 5.1% to 12.5% of retatrutide users in TRIUMPH-1 against 0.9% on placebo; Lilly says most cases were mild to moderate and resolved during treatment (Lilly, May 21, 2026). The Zepbound label reports it in 0.2% to 0.4% of users against 0.1% on placebo.
• Heart rate. Retatrutide’s phase 2 trial saw dose-dependent heart-rate increases that peaked at 24 weeks and then declined (Jastreboff et al., 2023). The Zepbound label reports a mean increase of 1 to 3 beats per minute. In a preprint health-record analysis, retatrutide trial participants averaged a 4.3 beats-per-minute rise at 3 months, which matched tirzepatide users did not show (Medscape, August 26, 2026).
• Blood pressure drops. In TRIUMPH-2, hypotension was more frequent on retatrutide than placebo, up to 6% on 12 mg against under 1% (Bellido et al., 2026).

The Zepbound label itself cautions that adverse reaction rates from different drugs’ trials “cannot be directly compared”, and the same caution applies here. Tirzepatide also carries a boxed warning about thyroid C-cell tumors seen in rats (Zepbound label, DailyMed); retatrutide’s full safety picture will come from its published trials and FDA review. Our guide to GLP-1 side effects and how people manage them covers the shared stomach effects in more depth.

What does each one cost?

Tirzepatide is a marketed prescription drug with a price you can look up, while retatrutide has no official price because it has not been approved. For what Zepbound and the other approved medicines cost with and without insurance, see GLP-1 costs without insurance. The storefront linked in this page’s “Where it’s sold” card listed retatrutide at $172 for one month, or $127 a month on a three-month plan, when we checked on October 12, 2026, and describes its vials as retatrutide combined with vitamin B12, a combination Lilly’s trials did not test. Lilly supplies its retatrutide only through its clinical trials (Lilly, May 21, 2026) and a limited expanded access program (ClinicalTrials.gov, NCT07629401), so products sold online under the name are not Lilly’s trial drug, and the trial results above describe Lilly’s drug only. Our comparison of branded and compounded GLP-1 access explains why that distinction matters.

What the community is saying about switching

The forum conversation is driven by people who stalled on tirzepatide and see retatrutide as the next step up. The Guardian reported that a Reddit community devoted to the drug draws more than 179,000 visits a week, and that an endocrinologist said most patients who ask her about it have reached the highest Zepbound dose without hitting their target weight, alongside people who like being at the cutting edge (The Guardian, August 31, 2026). We do not yet have our own community-tracker data for retatrutide, so this section summarizes published reporting rather than quoting posts.

Myth vs evidence on the “stronger Mounjaro” idea:

• “It’s the same drug, just turned up.” Not supported. The third receptor is a design difference, and it shows up in the side-effect profile (dysesthesia, heart rate), not only in the weight numbers.
• “You’ll lose 28%.” The trial averages describe Lilly’s drug under supervision. A preprint analysis of health records, not yet peer-reviewed, found people using retatrutide bought outside trials lost about 7.2% at 6 to 12 months, against 15.5% for trial participants in the same records and 7.7% for matched tirzepatide users (Medscape, August 26, 2026). In that observational data, with short follow-up, retatrutide bought outside trials did no better than real-world tirzepatide while still showing a heart-rate rise.
• “Skin sensitivity is just me.” It is a recognized signal: a Guardian interviewee described his skin becoming extra sensitive, which the paper called a common side effect, and it matches the dysesthesia rates in Lilly’s trials (The Guardian, August 31, 2026).

Where do they stand, and which is right for whom?

Tirzepatide is the option that exists today: an approved, prescribed medicine with a long published record. Retatrutide is the option people are waiting for. Lilly plans to submit it to the FDA in the first quarter of 2027 (Lilly, July 23, 2026), and until then the only routes to Lilly’s drug are its trials and a limited expanded access program for adults with a BMI of 35 or higher despite the highest available dose of a weight-management medicine, at least two serious or life-threatening obesity-related complications, and no way to join a trial (ClinicalTrials.gov, NCT07629401). Whether the extra receptor is worth the extra side effects for a given person is exactly what TRIUMPH-5 and the FDA review are set up to answer. The Treatment Report’s retatrutide overview covers the full trial program.

Status: Investigational; not FDA-approved. Lilly plans to submit it for approval in Q1 2027. What this means.

Sources

• Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept, Cell Metabolism 2022 (PubMed): retatrutide’s three receptor targets and the mouse findings on food intake and energy expenditure.
• Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, a Phase 2 Trial, NEJM 2023 (PubMed): 48-week phase 2 weight results, gastrointestinal side effects and the heart-rate signal.
• Eli Lilly, TRIUMPH-1 topline results, May 21, 2026: 80-week weight results by estimand, dosing schedule, adverse events, dysesthesia and discontinuation rates, and Lilly’s description of retatrutide as available only to trial participants.
• Eli Lilly, TRIUMPH-2 and TRIUMPH-3 topline results, July 23, 2026: the Q1 2027 FDA submission plan.
• Bellido V, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2), The Lancet 2026 (PubMed): 80-week weight results in type 2 diabetes, hypotension and dysesthesia rates.
• Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), NEJM 2022 (PubMed): 72-week tirzepatide weight results by dose.
• Zepbound (tirzepatide) Prescribing Information, DailyMed: mechanism, indications, adverse reaction rates, heart-rate and dysesthesia data, boxed warning.
• Mounjaro (tirzepatide) Prescribing Information, DailyMed: the type 2 diabetes indication.
• ClinicalTrials.gov, TRIUMPH-5 (NCT06662383): design and status of the retatrutide vs tirzepatide head-to-head trial.
• Medscape, Gray-market retatrutide, August 26, 2026: preprint health-record analysis of retatrutide used outside trials, including the heart-rate findings.
• The Guardian, August 31, 2026: reporting on the Reddit community, why people seek retatrutide, and the one-, two- and three-receptor comparison with Ozempic and tirzepatide.
• ClinicalTrials.gov, Pre-approval Expanded Access of Retatrutide (NCT07629401): Lilly’s expanded access listing and its eligibility criteria.

Educational information only, not medical advice. Trial figures are as reported in the cited publications and company releases as of October 12, 2026.